Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
50%(4/8)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_2
3
27%
Ph phase_1
6
55%
Ph phase_3
2
18%

Phase Distribution

6

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(4)
Terminated(5)

Detailed Status

Completed4
Terminated4
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 23 (27.3%)
Phase 32 (18.2%)

Trials by Status

completed436%
not_yet_recruiting218%
terminated436%
withdrawn19%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_1

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

NCT05322577
terminatedphase_3

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

NCT05111626
terminatedphase_1

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866
completedphase_3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05052801
withdrawnphase_1

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

NCT07146919
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05322577Phase 1

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Terminated
NCT05111626Phase 3

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Terminated
NCT05325866Phase 1

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Terminated
NCT05052801Phase 3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Completed
NCT07146919Phase 1

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Withdrawn
NCT07470840Phase 2

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Not Yet Recruiting
NCT06978062Phase 1

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Not Yet Recruiting
NCT05267470Phase 1

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Terminated
NCT03694522Phase 2

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Completed
NCT03343301Phase 1

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Completed
NCT02213289Phase 2

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11